Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity
Screening small molecule fragments has made it possible to identify pharmacological leads against otherwise hard to target hotspots on biomolecules, such as allosteric sites, rendering this approach a valuable alternative method of drug discovery
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
Roots Analysis has done a detailed report on Companion Diagnostics Development Services Market covering key aspects of the industry and identifying future growth opportunities
To order this 320+ page report, which features 120+ figures and 115+ tables, please visit this link
Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers
In the last couple of years, a record number of personalized therapeutic products were approved in the US, establishing an urgent need for companion diagnostics and causing many drug developers to actively seek external support and expertise
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
The numerous benefits offered by prefilled syringes, coupled to the growing self-medication trend, have led to the approval of a number of drugs in combination with such devices, resulting in an increase in need to outsource fill / finish operations
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity
To order this detailed 380+ page report, please visit this link
Key Inclusions
A detailed assessment of the current market landscape of psychedelic therapeutics, providing information on phase of development (commercial, clinical, preclinical, and discovery stage) of lead candidates, type of
To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link
Key Inclusions
A detailed review of the overall landscape of companies developing RNAi therapeutics, including information on phase of development (marketed, clinical, and
The potential therapeutic applications of RNAi were realized almost immediately after the phenomenon was first described; over the years, developers have gradually progressed their proprietary drug candidates with cautious optimism
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic
